Yu-Song Guo1, Cai-Xia Wang1, Jian Cao1, Jin-Liao Gao1, Xiao Zou1, Yi-Hong Ren1, Li Fan1. 1. 1 First Geriatric Cardiology Division of South Building, Chinese PLA General Hospital, Beijing 100853, China ; 2 Department of Nephrology, General Hospital of Beijing PLA Military Region, Beijing 100700, China ; 3 Department of Cardiology, Chinese PLA General Hospital, Beijing 100853, China.
Abstract
OBJECTIVE: To investigate the effects of probucol combined with atorvastatin on the serum oxidation index and lipid levels in patients diagnosed with acute coronary syndrome (ACS). METHODS: We randomly assigned 126 ACS patients (77 males and 49 females) to the control group (atorvastatin 20 mg/day, n=62) or the treatment group (atorvastatin 20 mg/day and probucol 750 mg/day, n=64). All the patients were followed up for 12 weeks. As oxidization indices, we measured the serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), oxidized LDL (ox-LDL), and paraoxonase-1 (PON1) before and after treatment. We also monitored the adverse effects of the drugs during the treatment. RESULTS: At baseline, there were no obvious differences (P>0.05) between the two groups (including age, gender, etc.). After 12 weeks of treatment, the ox-LDL levels in the treatment group were significantly lower while PON1 levels were significantly higher than those in the control group. There were no statistically significant difference between the two groups with respect to the side effects (P<0.05). CONCLUSIONS: The combined use of atorvastatin and probucol in ACS patients could reduce ox-LDL expression and increase PON1 expression more effectively than use atorvastatin alone.
RCT Entities:
OBJECTIVE: To investigate the effects of probucol combined with atorvastatin on the serum oxidation index and lipid levels in patients diagnosed with acute coronary syndrome (ACS). METHODS: We randomly assigned 126 ACS patients (77 males and 49 females) to the control group (atorvastatin 20 mg/day, n=62) or the treatment group (atorvastatin 20 mg/day and probucol 750 mg/day, n=64). All the patients were followed up for 12 weeks. As oxidization indices, we measured the serum levels of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), oxidized LDL (ox-LDL), and paraoxonase-1 (PON1) before and after treatment. We also monitored the adverse effects of the drugs during the treatment. RESULTS: At baseline, there were no obvious differences (P>0.05) between the two groups (including age, gender, etc.). After 12 weeks of treatment, the ox-LDL levels in the treatment group were significantly lower while PON1 levels were significantly higher than those in the control group. There were no statistically significant difference between the two groups with respect to the side effects (P<0.05). CONCLUSIONS: The combined use of atorvastatin and probucol in ACS patients could reduce ox-LDL expression and increase PON1 expression more effectively than use atorvastatin alone.
Authors: Yosuke Kayama; Uwe Raaz; Ann Jagger; Matti Adam; Isabel N Schellinger; Masaya Sakamoto; Hirofumi Suzuki; Kensuke Toyama; Joshua M Spin; Philip S Tsao Journal: Int J Mol Sci Date: 2015-10-23 Impact factor: 5.923